肠易激综合征结肠形态重建4种分型方法的探讨

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (707 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To discuss the practical application value of colonic morphology reconstruction (CTC) in irritable bowel syndrome (IBS). Methods From January 2014 to January 2016, in Chengde Central Hospital, 110 patients with IBS were selected. all patients were given colonic morphology reconstruction by MSCT, they were divided into 4 types by CTC data: length type, twisted type, spastic type and inability type, The correlativity of all the clinical symptoms of different types of IBS was analyzed. Results The results showed 27 cases (24.55%) were length type, 22 cases (20.00%) were distorted type, 37 cases (33.64%) were spasticity type and 24 cases (21.82%) were weakness type, colon curvature and total length of 4 types were compared, the differencea were statistically significant (P < 0.05), constipation, incomplete defecation, stimulated diarrhea and abdominal distension of 4 types were compared, the differencea were statistically significant (P < 0.05). The lengthy type was positively correlated with constipation (r = 0.943, P < 0.05), distortion was positively correlated with poor defecation (r = 0.876, P < 0.05), spasticity was positively correlated with postganglionic diarrhea (r = 0.815, P < 0.05), and insufficiency was positively correlated with bloating (r = 0.973, P < 0.05). Conclusion IBS can be subdivided into four types by MSCT reconstruction, and each type has typical clinical symptoms, which can provide experimental basis for clinical diagnosis and treatment.

Key words： Irritable bowel syndrome Morphological reconstruction Influencing factors Correlation MSCT

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XUE Runguo1 XUAN Jianxin2 CUI Bing3 SU Bin1 XIN Hong4 CUI Baoji1 LI Jianhui1

Cite this article:

XUE Runguo1 XUAN Jianxin2 CUI Bing3 SU Bin1 XIN Hong4 CUI Baoji1 LI Jianhui1. Discussion of 4 classification methods of colonic morphology reconstruction in irritable bowel syndrome[J]. 中国医药导报, 2017, 14(25): 123-126.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I25/123

[1] 陈丽萍，王世军，卢岩，等.针刺治疗腹泻型肠易激综合征研究进展[J].山东中医杂志，2015，4（1）：71-73.
[2] 包春辉，黄任佳，王硕硕，等.灸法对肠易激综合征慢性内脏痛镇痛效应的研究与展望[J].中国组织工程研究，2015，19（15）：2431-2435.
[3] 谭晓慧，王滨，刘晓辉.浅析肠易激综合征的病因病机及治疗原则[J].内蒙古医科大学学报，2015，37（S1）：103-106，117.
[4] 徐小慧.肠易激综合征护理干预的研究进展[J].当代护士：中旬刊，2014（2）：10-12.
[5] Manolakis AC，Christodoulidis G，Kapsoritakis AN，et al. α2-Heremans-schmid glycoprotein （fetuin A） downregulation and its utility in inflammatory bowel disease [J]. World J Gastroenterol，2017，23（3）：437-446.
[6] 苏敏，王凤云，卞兆祥，等.中西医结合治疗IBS-D临床观察文献分析[J].北京中医药，2013，32（11）：816-819.
[7] 谢秀俊，熊俊，陈日新.灸法治疗肠易激综合征的临床证据[J].时珍国医国药，2014，25（3）：741-744.
[8] 魏晓晶，王佩蓉.肠易激综合征各亚型患者的抑郁焦虑状况及其影响因素分析[J].中国现代医生，2014，52（28）：134-137.
[9] Edebol-Carlman H，Ljótsson B，Linton SJ，et al. Face-to-face cognitive-behavioral therapy for irritable bowelsyndrome：the effects on gastrointestinal and psychiatric sym?鄄ptoms [J] .Gastroenterol Res Pract，2017，2（12）：84-87.
[10] Lucak S，Chang L，Halpert A，et al. Current and emergent pharmacologictreatments for irritable bowel syndrome with diarrhea：evidence-based treatmentin practice [J]. Therap Adv Gastroenterol，2017，10（2）：253-275.
[11] 李琳，张声生.近十年肠易激综合征外治法研究概况[J].四川中医，2013（1）：137-142.
[12] 李梅，张苏闽，刘翬.针灸治疗肠易激综合征临床研究概况及选穴规律探讨[J].辽宁中医药大学学报，2013， 31（3）：122-124.
[13] Buono JL，Carson RT，Flores NM. Health-related quality of life，work productivity，and indirect costs among patients with irritable bowel syndrome with diarrhea [J]. Health Qual Life Outcomes，2017，15（1）：35-36.
[14] Nwosu BU，Maranda L，Candela N. Vitamin D status in pediatric irritable bowel syndrome [J]. PLoS One，2017，2（2）：344-345.
[15] Zielińska M，Fichna J，Bashashati M，et al. G protein-coupled estrogen receptor and estrogen receptor ligands regulate colonic motility and visceral pain [J]. Neurogastroenterol Motil，2017，2（12）：45-47.
[16] Tuck C，Barrett J. Re-challenging FODMAPs：the low FODMAP diet phase two [J]. J Gastroenterol Hepatol，2017，2（4）：11-15.
[17] O'Keeffe M，Lomer MC. Who should deliver the low FODMAP diet and what educational methods are optimal：a review [J]. J Gastroenterol Hepatol，2017，32（Suppl 1）：23-26.
[18] Malakar S.Bioactive food chemicals and gastrointestinal symptoms： a focus of salicylates [J]. J Gastroenterol Hepatol，2017，32（11）：73-77.
[19] Méance S，Giordano J，Chuang E et al. Food regulations：low FODMAP labeling and communication goals [J]. J Gastroenterol Hepatol，2017，4（32）：62-63.
[20] Chey WD，Lembo AJ，Rosenbaum DP. Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome： a phase 2，randomized，placebo-controlled efficacy and safety trial [J]. Am J Gastroenterol，2017，3（15）：34-35.
[21] 彭珊，赵钢，李春艳，等.肠易激综合征的发病机制研究进展[J].中国医药导报，2016，13（6）：54-57.